| On Friday 4 October: |
| 13:00 - 13:15 |
Registration
|
| 13:15 - 13:30 |
Welcome & introduction with pre-symposium survey results
|
| 13:30 - 14:20 |
Early phase achievements & proposed improvements from both regulatory & industry perspective (speaker TBC)
|
| |
How to consolidate Belgium as an early clinical trial hub: challenges and opportunities in an evolving landscape by Nathalie Lambot (pharma.be)
|
| |
Panel discussion
|
| 14:20 - 14:40 |
The impact of EU-CTR on clinical vaccine research in Belgium by Isabel Leroux-Roels (UZ Gent)
|
| 14:40 - 15:00 |
Early phase studies with genetically modified (GMO) vaccines, a case study by Bruno Speder (AstriVax)
|
| 15:00 - 15:30 |
Coffee break
|
| 15:30 - 15:50 |
Modus operandus and role of BAREC in the Belgian landscape by Pieter Moons (BAREC)
|
| 15:50 - 16:30 |
Data transparancy rules from regulatory perspective by Nele Steens (FAMHP)
|
| |
EU Clinical Trial Regulation and Data Transparency: Implications for protecting our Innovation by Maarten Timmers (Johnson & Johnson)
|
| |
Panel discussion
|
| 16:30 - 16:50 |
CTR and academic research by Minne Casteels (KU Leuven)
|
| 16:50 - 17:00 |
Symposium wrap-up
|
| 17:00 - 18:00 |
Closing drink
|
